Breast cancer genetic testing from the perspective of precision medicine

doi:10.3877/cma.j.issn.1674-0807.2018.06.003

Abstract

Abstract:

Precision medicine is the future trend for breast cancer treatment. With the development of gene sequencing technology and the decline of detection cost, genetic testing is widely used in clinical practice, and has gradually become one of the important factors for clinical decision-making. However, the credibility of the test results and the feasibility of the treatment regimen still need to be improved. If the current method of genetic testing has reliable result, clear mechanism, definitive function and availability of effective drugs for targeted therapy, it can provide clinical guidance. For many genes with unclear mechanisms and functions, the accuracy of genetic testing cannot be guaranteed and more clinical trials are needed, so it is not recommended to guide clinical decision-making. We introduced the testing of three representative genes, including BRCA1/2, ESR1 and PIK3CA, to explore the clinical significance of breast cancer genetic testing from the perspective of precision medicine.

Key words: Breast neoplasms, Genes, BRCA1, Early detection of cancer, Precision medicine

Hengyu Li, Yuan Sheng. Breast cancer genetic testing from the perspective of precision medicine[J]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(06): 329-334.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2018.06.003

https://zhrxbzz.cma-cmc.com.cn/EN/Y2018/V12/I06/329

References 41

[1]	Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21[J]. Science, 1990, 250(4988):1684-1689.
[2]	Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer[J]. Hum Mol Genet, 2001, 10(7):705-713.
[3]	Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention[J]. Science, 2014, 343(6178):1466-1470.
[4]	《BRCA数据解读中国专家共识》编写组. BRCA数据解读中国专家共识[J]．中华病理学杂志，2017，46(5):293-297.
[5]	Sun J, Meng H, Yao L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res, 2017, 23(20):6113-6119.
[6]	Li J, Jing R, Wei H, et al. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer [EB/OL]. [2018-05-01]. URL
[7]	Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer[J]. Breast Cancer Res Treat, 2016, 158(3):455-462.
[8]	Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study[J]. Lancet Oncol, 2018, 19(2):169-180.
[9]	Zhao W, Steinfeld JB, Liang F, et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing[J]. Nature, 2017, 550(7676):360-365.
[10]	Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial [J]. Nat Med, 2018, 24(5):628-637.
[11]	Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial[J]. JAMA Oncol, 2017, 3(10):1378-1385.
[12]	Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6):523-533.
[13]	Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation[J]. N Engl J Med, 2001, 345(3):159-164.
[14]	Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer[J]. Int J Clin Oncol, 2017, 23(1):45-51.
[15]	Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group[J]. J Clin Oncol, 2004, 22(6):1055-1062.
[16]	Contant CM, Menke-Pluijmers MB, Seynaeve C, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation[J]. Eur J Surg Oncol, 2002, 28(6):627-632.
[17]	Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers [J]. J Clin Oncol, 2004, 22(12): 2328-2335.
[18]	Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project[J]. J Clin Oncol, 2005, 23(19):4275-4286.
[19]	Wong SM, Freedman RA, Sagara Y, et al. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer[J]. Ann Surg, 2016, 265(3):581-589.
[20]	Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients[J]. J Natl Cancer Inst, 2010, 102(6):401-409.
[21]	Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer[J]. Cochrane Database Syst Rev, 2018, 4(1):CD002748.
[22]	Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer[J]. N Engl J Med, 2016, 374(5):454-468.
[23]	Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer[J]. J Clin Oncol, 2006, 24(16): 2437-2443.
[24]	Metcalfe K, Lynch HT, Ghadirian P, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers[J]. Breast Cancer Res Treat, 2011, 127(1):287-296.
[25]	Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2014, 144(3):443-455.
[26]	Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination[J]. JAMA, 2004, 292(11): 1317-1325.
[27]	Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging[J]. J Clin Oncol, 2011, 29(13): 1664-1669.
[28]	Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging[J]. JAMA, 2006, 295(20):2374-2384.
[29]	Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results[J]. Invest Radiol, 2011, 46(2):94-105.
[30]	邵志敏，徐兵河，任国胜．中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识[J]. 中国癌症杂志，2018，28(10):787-800.
[31]	Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013, 368(13):1199-1209.
[32]	林健，贾淞淋，方敏，等．早期乳腺癌患者循环肿瘤细胞TP53、磷脂酰肌醇-3激酶基因突变分析及其与患者临床病理特征的相关性[J]．中国临床医学，2018，25 (2):210-216.
[33]	Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genet, 2013, 45(12):1439-1445.
[34]	Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25):2961-2968.
[35]	Weir HM, Bradbury RH, Lawson M, et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models[J]. Cancer Res, 2016, 76(11): 3307-3318.
[36]	Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer[J]．N Engl J Med, 2015, 373(3): 209-219.
[37]	Chen L, Yang L, Yao L, et a1. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients[J]. Nat Commun, 2018, 9(1):1357.
[38]	Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013, 368(13):1199-1209.
[39]	Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2018, 19(1): 87-100.
[40]	Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial[J]. Lancet, 2002, 359(9324): 2131-2139.
[41]	Dowsett M, Cuzick J, Wale C, et a1. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study[J]. J Clin Oncol, 2010, 28(11):1829-1834.

Please choose a citation manager

Content to export